相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
John Mascarenhas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A. Pardanani et al.
LEUKEMIA (2013)
AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL
M. J. Stankiewicz et al.
LEUKEMIA (2013)
mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
Costanza Bogani et al.
PLOS ONE (2013)
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Ayalew Tefferi
BLOOD (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
Yan Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2012)
EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L
G. Wernig et al.
LEUKEMIA (2012)
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients
T. L. Lasho et al.
LEUKEMIA (2012)
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia
C. Simioni et al.
LEUKEMIA (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification
Melanie G. Cornejo et al.
BLOOD (2011)
Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A phase-2 trial of low-dose pomalidomide in myelofibrosis
K. H. Begna et al.
LEUKEMIA (2011)
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients
A. Pardanani et al.
LEUKEMIA (2011)
Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up?
A. Tefferi
LEUKEMIA (2011)
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Fabio P. S. Santos et al.
BLOOD (2010)
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
Priya Koppikar et al.
BLOOD (2010)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W. Tyner et al.
BLOOD (2010)
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
Hajime Akada et al.
BLOOD (2010)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia
Francesca Chiarini et al.
CANCER RESEARCH (2010)
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis et al.
CLINICAL CANCER RESEARCH (2010)
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Sachie Marubayashi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
Jieru Meng et al.
PLOS ONE (2010)
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
Yongchao Wang et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms
Lizz F. Grimwade et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation
Jacob P. Laubach et al.
EXPERIMENTAL HEMATOLOGY (2009)
Mutations of ASXL1 gene in myeloproliferative neoplasms
N. Carbuccia et al.
LEUKEMIA (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Prevalence of polycythemia vera and essential thrombocythemia
Xiaomei Ma et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
Philip A. Beer et al.
BLOOD (2008)
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
Michael G. Kharas et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
V. Guerini et al.
LEUKEMIA (2008)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Stefan O. Ciurea et al.
BLOOD (2007)
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Virginia M. Zaleskas et al.
PLOS ONE (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera
V Ugo et al.
EXPERIMENTAL HEMATOLOGY (2004)
Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles
K Uozumi et al.
LEUKEMIA (2000)